ECO Animal Health Group PLC · LSE:EAH

ECO Animal Health — Investor Day (November 2026)

56 slides from ECO Animal Health's investor day presentation, Nov 11, 2026

  1. Slide 1: Capital Markets Day

    Capital Markets Day November, 2026 1

  2. Slide 2: Disclaimer

    Disclaimer § This presentation is incomplete without reference to, and should be viewed indications contained in any such potential forward-looking statements. No solely in conjunction with, the oral briefing which accompanies it. The representation or warranty of any kind is made with respect to th

  3. Slide 3: What you will hear today

    What you will hear today Commercial proof Future products Value R&D portfolio progress, geographic expansion and and business development ® progress in Europe, followed by ECOVAXXIN ® TOXOPLAS Portfolio and corporate a producer perspective ECOPS valuation, with time for investor PRR V S V questions

  4. Slide 4: Agenda

    Agenda Dr. David Hallas 1 10:00 Turning vision into strategy and execution ECO Chief Executive Officer Aivlosin® update & ECOVAXXIN® MS commercial progress Mr. Andrew Buglass 2 10:15 in EU Chief Commercial Officer 3 10:30 Experiences with ECOVAXXIN® MS Egg producer 4 10:35 ECOVAXXIN® MS geo-expansio

  5. Slide 5: Turning vision into strategy and execution

    The investment outlook: How is Aivlosin® Turning vision into performing in its established markets? strategy and What evidence supports execution the ECOVAXXIN® MS launch and expansion? Priorities driving revenue and returns How can the pipeline Dr. David Hallas | CEO and partnerships add to future

  6. Slide 6: Three priorities for the next phase

    Three priorities for the next phase Current New Business portfolio products development Defend Aivlosin® sales and Launch vaccines well, expand Add complementary products margins through customer into new geographies and and capabilities where returns focus, supply reliability and progress the pipel

  7. Slide 7: Defend the base, earn the next sale

    defend the base, earn the next sale Customer Availability Margin Key accounts, technical Supply planning and Pricing discipline, cost service and local dependable product improvement and market plans delivery generic defence 7

  8. Slide 8: New products: launch, expand, then scale

    New products: launch, expand, then scale ® in Europe Translate the EU launch into producer adoption, supported by field teams and distribution Expansion beyond Europe Advance registration and prepare the route to market before each launch The wider portfolio Prioritise evidence, manufacturing readin

  9. Slide 9: Capabilities that make growth possible

    Capabilities that make growth possible R&D Partnerships Manufacturing People Focus on prevention and Screen products and Secure vaccine capacity Add commercial, products with clear capabilities that and build a resilient technical and regulatory differentiation and strengthen the portfolio supply ch

  10. Slide 10: Aivlosin update & ECOVAXXIN MS commercial progress in EU

    Aivlosin® update & ECOVAXXIN® MS commercial progress in EU + Mr. Andrew Buglass | CCO 10

  11. Slide 11: Global sales

    global sales Aivlosin®: 11x growth since FY07, led today by the Americas Aivlosin® sales by region, £m. 100 Regions shown from FY18, the first year they were reported 11x growth since FY07, 51% of sales now 80 from £7.1m to from the c.£81.5m (c.14% a Americas, up year) from 27% in FY18 60 40 Growth

  12. Slide 12: How have we grown Aivlosin?

    How have we grown Aivlosin®? Geo-expansion Adding species now registered in 70 swine > chickens > turkeys countries > laying hens Adding new Technical service formulations in-barn advice, elimination 4.25% Premix, Water Soluble programmes and use in complex Granules, 17% Premix diseases such as PRRS

  13. Slide 13: How will ECO continue to grow

    How will ECO continue to grow Capturing a greater share of margin reducing cost of goods / managing selling price / route to market e.g. going direct in Brazil Excellent commercial execution through our own teams and distribution Generic defence New technology partners I.P defence, quality – generic

  14. Slide 14: Key markets: China swine

    Key markets: China swine China: deep losses are forcing a rapid sow herd reduction Producers have lost money since late 2022; the herd is shrinking fast and a price recovery is expected in 2027 China breeding sow herd, million head Down c.3.6m in nine months, c.92,000 a week; government target ~£1.2

  15. Slide 15: ECOVAXXIN MS key benefits

    ® key benefits A best-in-class live vaccine against Mycoplasma synoviae Why it matters to layer and breeder producers, and to ECO Broad protection Simple eye-drop Proven immunity* Why it matters Reduces air sac and foot dosing Immunity starts 4 weeks pad lesions (synovitis), Given as eye drops to af

  16. Slide 16: ECOVAXXIN MS EU launch status

    ® EU launch status Approved across the EU; partners in place for 94% of layer hens November 2026: selling in 3 markets, 11 more receiving first stock this month, Italy in December Approved in all 27 EU markets 19 EU MARKETS · 360M LAYER HENS Centralised EU approval, 30 Dec 2025 ES PT PL NL FR 46M 10

  17. Slide 17: Post launch: commercial roll-out

    ® Post launch: commercial roll-out Seven partners cover 337M EU layer hens (94%), plus South Africa Distribution agreements, first stock and repeat stock by partner, May 2026 – Mar 2027 Market · hen numbers May ’26 Jun Jul Aug Sep Oct Nov Dec Jan ’27 Feb Mar Spain & Portugal · 56M hens Poland · 50M

  18. Slide 18: Early commercial performance

    ® early commercial performance £230k sold to date; c.£1.0m expected for the full year Latest estimate of FY27 (year to March 2027) ECOVAXXIN® MS sales by market £0 £125K £250K BE, NL, FR, DE, AT £230k H1 sales (April–September 2026), all from Poland and Spain & Portugal Italy Spain & Portugal ~£1M P

  19. Slide 19: Learnings and next steps

    ® learnings and next steps Lessons from the launch, and priorities to March 2027 What the European roll-out has taught us, and where we will focus next What we have learnt Next steps Price to market value Convert first orders into repeat orders Correct value-based pricing at end-user level via count

  20. Slide 20: Customer experiences with ECOVAXXIN MS

    Customer experiences with Egg Producer (recorded video) 20

  21. Slide 21: Geo-expansion

    ® Geo-expansion Building a global registration model Dr. Set Yong | Head of Quality and Regulatory 21

  22. Slide 22: Global expansion, where we are today

    ® global expansion, where we are today Market opportunity and layer population (millions) Estimated regulatory approval timelines (2026-2031) 465M 2026 EU USA 41M Saudi Arabia 30M 460M 2027 GB Canada 100M Argentina 318M 55M 2028 Thailand 210M 18M 175M 60M 35M 2029 Egypt 62M 155M 2030 Brazil Mexico x

  23. Slide 23: How we are de-risking the rollout

    How we are de-risking the rollout One proven dossier, many markets Manufacturing & supply readiness Our EU approval and US data form the core of every Our EU manufacturing partner’s GMP certification is submission, so no market starts from scratch. recognised by many international regulators, reduci

  24. Slide 24: Outlook: from registrations to a repeatable expansion engine

    Outlook: from registrations to a repeatable expansion engine Our momentum: How we will deliver: Regulatory readiness 5(+1) dossiers already with regulators, including the USA and Great Britain High-quality dossiers and active engagement with authorities (import licence submitted for Saudi Arabia) Cr

  25. Slide 25: Business development

    Business development Opportunities and strategy Dr. Andrew Winder | Head of Business Development 25

  26. Slide 26: Evolving towards a prevention-focused future

    Evolving towards a prevention-focused future Building on and as ECO expands beyond its traditional therapeutics business New vaccine launches drive the transition ® • demonstrates how ECO can use its established network to launch preventative solutions BD can accelerate access to technology • Strate

  27. Slide 27: ECO's BD strategy: clear guardrails for in-licensing and M&A

    ECO’s BD strategy: clear guardrails for In-licensing and M&A Focus where ECO can win Deepen selected disease categories across swine, poultry and small ruminant Build differentiated positions in animal Target near-term value health while Acquire, license or distribute capitalising on strategic marke

  28. Slide 28: Partnerships and M&A: short-, mid- and long-term

    Partnerships and M&A: short-, mid- and long-term Short term Mid term Longer term Core priorities Selective opportunities Future opportunities In-licensing / Out-licensing R&D pipeline Sales force expansion Co-development Entry into adjacent categories Manufacturing infrastructure Relative timing bas

  29. Slide 29: In-licensing deals: a growing strategic pillar

    In-licensing deals: a growing strategic pillar Deal overview Deal overview Collaboration with global academic Co-development with a recognised start- leader in poultry medicine for up to accelerate entry into a new ECOVAXXIN® MS & MG accessible species Strategic value Strategic value • Benefits over

  30. Slide 30: Four routes driving business development

    Four routes driving business development 01 Broad industry engagement 02 Leveraging proven partnerships Active discussions with animal health companies, Live development projects with Vaxinano, start-ups, investment banks, consultants and research Quantoom and the University of Georgia; recent organ

  31. Slide 31: Vaxinano introduction

    introduction Recorded video Pr. Didier Betbeder | CEO Vaxinano 31

  32. Slide 32: R&D Portfolio Progress

    R&D Portfolio Progress Innovation driving veterinary medicine forwards Dr. Nathalie Desloges | Head of Development (Poultry) 32

  33. Slide 33: R&D project portfolio roadmap

    R&D project portfolio roadmap Mid- and late-stage projects ECOPSV (porcine systemic vaccine) ECOVAXXIN® PCV2/MHP 1st Approval: 1H’31 (US) 1st Approval: 2H’28 (US) Global PYR*: £11.5m (2038) Global PYR*: £16.3m (2038) ® Approval: 1H’28 (EU) Global PYR*: £12.2m (2037) PRRSVmAb ® 1st Approval: 1H’30 (U

  34. Slide 34: ECOVAXXIN MS: extending duration of immunity

    ®: extending duration of immunity Evaluating protection against airsacculitis caused by Mycoplasma synoviae provided by ECOVAXXIN® MS in laying birds at 44 weeks post-vaccination • 49 birds per treatment group challenged with M.synoviae at 44 weeks after vaccination • Air sac lesions evaluated 7 day

  35. Slide 35: ECOVAXXIN MS US field safety data acceptance

    ® US field safety data acceptance Evaluating the safety of ECOVAXXIN® MS in field conditions in the US ® • Study required for regulatory submission in the US. • Over 170,000 female birds vaccinated at 4 weeks of age with a single dose of ECOVAXXIN® MS via eye drop. Safety Data Acceptance Following i

  36. Slide 36: ECOVAXXIN MG duration of immunity for Europe

    ® duration of immunity for Europe Mycoplasma gallispeticum causes severe chronic respiratory disease and decreased egg production, resulting in major economic losses in poultry. Tracheal Thickness Egg Production 25. 0 Evaluating the duration of immunity of 300 250 ECOVAXXIN® MG when administered to

  37. Slide 37: ECOVAXXIN MG dossier submission to the European Medicines Agency

    ® dossier submission to the European Medicines Agency A novel lyophilised vaccine for Mycoplasma gallisepticum as efficacious as market leading products but without the side effects associated with live MG vaccines. ® 4w 1st APPROVAL: 1H’28 (EU) distribution and 4 week onset protection against: prov

  38. Slide 38: ECOFLOR field efficacy

    ® field efficacy Evaluating the field efficacy of ECOFLOR in the treatment of acute cases of swine respiratory disease • Data from 4 European field sites • Cure success evaluated 10 days post treatment Group No. of pigs Cure Success D10 ® 104 84% Market leader (tulathromycin) 104 81% ECOFLOR® 1st AP

  39. Slide 39: Mid-stage R&D projects

    Mid-stage R&D projects ECOVAXXIN® Pivotal study programme starts early-2027 PCV2-MHP 1st APPROVAL: 2H’28 (US) Stage: ED Technology transfers underway to EU/USA manufacturing partners Global NPV: £17.8m Global PYR: £16.3m USDA submissions initiated Some PCV2 market price erosion due to highly competi

  40. Slide 40: Mid-stage R&D projects

    Mid-stage R&D projects PRRSVmAb POC phase extended to optimize PK profile via multiple rounds of protein engineering 1st APPROVAL: 1H’30 (US) Stage: POC Lead candidate entering decisive reproductive efficacy evaluation Global NPV and PYR* against NA-PRRSV challenge. Study completes in the near term

  41. Slide 41: Mid-stage R&D projects (new entries)

    Mid-stage R&D projects (new entries) ECOPSV (porcine systemic vaccine) 1st APPROVAL: 1H’31 (US) Stage: POC research early CMC optimisation successfully Global NPV: £10.6m agreement in progress with two completed piglet Global PYR: £11.5m signed global CMC experts efficacy with prototype ECOVAXXIN® T

  42. Slide 42: Timelines and progress

    Timelines and progress 2025 2026 2027 2028 2029 2030 2031 1H Q3 2H 1H Q1 2H 1H Q3 2H 1H Q1 2H 1H 2H Q3 1H 2H 1H 2H ® Approved Dec25 EU ® Approval by end-2H’26 (on-track) US ® Approval 1H’28 EU 3Q’27 ® Approval 2H’28 US 4Q’26 Approval 2H’28 ECOFLOR ® EU 1Q’27 Approval 2H’28 ECOVAXXIN® PCV2/MHP US 1Q’

  43. Slide 43: R&D portfolio and corporate valuation

    R&D portfolio and corporate valuation Mr. Chris Wilks | CFO / Mr. Charles Bardswell | Deputy CFO 43

  44. Slide 44: Group results – simplified

    Group results – simplified1 Revenue excl China (£’M) Gross margin excl China (£’M) EBITDA excl China, R&D (£’M) 80. 0 54% 12. 0 70.0 52% 10. 0 60. 0 50% 8.0 50. 0 48% 40. 0 46% 6.0 30. 0 44% 4. 0 20. 0 42% 2.0 10. 0 40% 0.0 38% 0.0 Mar-22 Mar-23 Mar-24 Mar-25 Mar-26 Mar-22 Mar-23 Mar-24 Mar-25 Mar-2

  45. Slide 45: PE ratio – proforma basis

    PE ratio – proforma basis PE ratio in month after results (EPS: R&D out, China = dividend) Year ended 31 March 16 Group excl R&D 2022 2023 2024 2025 2026 14 Adjusted EPS – ex China 12 8.0 9.1 8.9 11.2 14.4 but incl divi rec’d (p) 10 Results date 31Aug 10Jul 15Jul 14Jul 15Jul 8 6 Share price – ave fo

  46. Slide 46: R&D Portfolio and corporate valuation - approach

    R&D Portfolio and corporate valuation - approach • Valuation of Group excluding R&D - Multiple of earnings • Valuation of ECOVAXXIN® MS in Europe – DCF • Valuation of ECOVAXXIN® MS in markets where approval not yet received – Risked DCF • Valuation of R&D Portfolio – Risked DCF • Valuation of PRRSVm

  47. Slide 47: Valuation of group excluding R&D - multiple of earnings basis

    Valuation of group excluding R&D - multiple of earnings basis Calculation of base business valuation 31-Mar-26 £’m Profit of the group after tax 3.6 R&D costs (net of tax effects) 6.7 China: net effect of treating as dividend in flow only (0.7) Total 9.6 P/E ratio 12 Enterprise value 115 47

  48. Slide 48: Valuation of ECOVAXXIN MS in Europe – DCF

    Valuation of ® in Europe – DCF £16.2m £3.8m 61% NPV (DCF, pre-tax) Peak revenue Gross margin ECOVAXXIN® MS Europe – annual cash flow (£m)* Key assumptions 4.5 4.0 Launch: Jul26 in 10 registered countries; further EU 3.5 from 2Q’27 3.0 Market: >400m hens commercialised in EU; 2.5 incidence 85%, vacci

  49. Slide 49: Valuation of ECOVAXXIN MS in other markets

    Valuation of ® in other markets Approval not yet received – Risked DCF £27.7m Risked NPV (rNPV) £30.4m NPV (unrisked) 91% PTRS £14.9m Peak revenue (2038) ECOVAXXIN® MS other markets – ECOVAXXIN® MS other markets – revenue by region (£m, unrisked) 16. 0 value bridge (£m) 35 14. 0 30 12. 0 25 10. 0 8.

  50. Slide 50: Valuation of selected R&D Portfolio

    Valuation of selected R&D Portfolio (excl PRRSVmAb) – Risked DCF Selected R&D portfolio – NPV and risked NPV (£m, pre-tax) Revenue – ECOVAXXIN MS + MG (£m, unrisked) Portfolio total: NPV £97.1m / rNPV £57.0m 35 29 31 29.6 30 24 NP V (u nrisked ) 20.9 rNP V 25 20 18.3 17.7 17.6 17.8 20 16 11.0 9.3 10

  51. Slide 51: Valuation of PRRSVmAb – key pivotal trial ongoing

    Valuation of PRRSVmAb – key pivotal trial ongoing c£275m Addressable market p.a. c£70m Doses p.a. – 9 markets £0-133m Indicative value range PRRSVmAb – addressable market by region (£m p.a.) Development status • Two manufacturing routes progressing in parallel – China (29.9m dos es) £132m CHO and ye

  52. Slide 52: R&D portfolio – cost to go

    R&D portfolio – cost to go £20.8m Total cost to go, 2027-30 £15.0m / £5.8m £9.5m (2028) (undiscounted) R&D / Tech transfer Peak spend year Cost to go by project (£m, undiscounted, from 2027) Spend by year – R&D and tech transfer (£m) 9.5 10.0 9.0 EcoFlor® 0.7 8.0 7.0 ECOVAXXIN MG® 1.2 1.1 5.1 6.0 5.

  53. Slide 53: Summary: total sum of parts

    Summary: total sum of parts Component (£m) Method Gross (unrisked) Risk discount Net value % of EV £216m Group excl R&D Multiple of earnings (P/E 12: 115.0 - 115.0 53% ECOVAXXIN MS - Europe DCF 16.2 - 16.2 7% ECOVAXXIN MS – other markets Risked DCF 30.4 (2.7) 27.7 13% Enterprise value R&D Portfolio

  54. Slide 54: Summary

    Summary Moving from pipeline potential to delivery Dr. David Hallas | CEO 54

  55. Slide 55: Summary: moving from pipeline potential to delivery

    Summary: moving from pipeline potential to delivery Growing demand Investing in Global commercial Expanding gross for livestock disease developing and platform in over 70 margins prevention defending Aivlosin® countries franchise £ ECOVAXXIN® MS Focused pipeline in Enhanced business Strong balance l

  56. Slide 56: Q&A

    Q&A 56

ECO Animal Health Group — Investor Day (November 2026) on 6ix